(NASDAQ: BCDA) Biocardia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Biocardia's earnings in 2025 is -$7,946,000.On average, 1 Wall Street analyst forecast BCDA's earnings for 2025 to be -$5,709,606, with the lowest BCDA earnings forecast at -$5,709,606, and the highest BCDA earnings forecast at -$5,709,606. On average, 1 Wall Street analyst forecast BCDA's earnings for 2026 to be -$6,224,407, with the lowest BCDA earnings forecast at -$6,224,407, and the highest BCDA earnings forecast at -$6,224,407.
In 2027, BCDA is forecast to generate -$6,645,607 in earnings, with the lowest earnings forecast at -$6,645,607 and the highest earnings forecast at -$6,645,607.